Tyme announces interim phase II data for SM-88 in prostate cancer at ASCO GU Symposium

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Tyme Technologies Inc. announced efficacy and safety data from an ongoing phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login